1
|
Kissinger ST, O'neil E, Li B, Johnson KW, Krajewski JL, Kato AS. Distinctive neurophysiological signatures of analgesia after inflammatory pain in the ACC of freely moving mice. J Neurosci 2024:e2231232024. [PMID: 38755005 DOI: 10.1523/jneurosci.2231-23.2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 04/11/2024] [Accepted: 05/01/2024] [Indexed: 05/18/2024] Open
Abstract
Preclinical assessments of pain have often relied upon behavioral measurements and anesthetized neurophysiological recordings. Current technologies enabling large scale neural recordings, however, have the potential to unveil quantifiable pain signals in conscious animals for preclinical studies. Although pain processing is distributed across many brain regions, the anterior cingulate cortex (ACC) is of particular interest in isolating these signals given its suggested role in the affective ('unpleasant') component of pain. Here, we explored the utility of the ACC towards preclinical pain research using head-mounted miniaturized microscopes to record calcium transients in freely moving male mice expressing GCaMP6f under the Thy1 promoter. We verified the expression of GCaMP6f in excitatory neurons and found no intrinsic behavioral differences in this model. Using a multimodal stimulation paradigm across naive, pain, and analgesic conditions, we found that while ACC population activity roughly scaled with stimulus intensity, single cell representations were highly flexible. We found only low magnitude increases in population activity after CFA, and insufficient evidence for the existence of a robust nociceptive ensemble in the ACC. However, we found a temporal sharpening of response durations and generalized increases in pairwise neural correlations in the presence of the mechanistically distinct analgesics gabapentin or ibuprofen after (but not before) CFA induced inflammatory pain. This increase was not explainable by changes in locomotion alone. Taken together, these results highlight challenges in isolating distinct pain signals amongst flexible representations in the ACC but suggest a neurophysiological hallmark of analgesia after pain that generalizes to at least two analgesics.Significance Statement Our study measured neural activity in the anterior cingulate cortex (ACC) of transgenic mice to improve measures of pain and analgesia in preclinical models. We found that although ACC population activity scaled with stimulus intensity and could be decoded, single cell representations of sensory stimuli were flexible. Low magnitude increases in ACC population activity were observed after pain, but subpopulations with specific activity changes driven by pain/analgesia were difficult to disambiguate from intrinsic variability. Interestingly, responses were temporally sharpened and exhibited increased cell to cell correlations in the presence of two distinct analgesics after CFA but not before. These distinct neural signatures of analgesia occurring only after pain may broaden our understanding of central mechanisms of pain and analgesia.
Collapse
Affiliation(s)
- Samuel T Kissinger
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| | - Estefania O'neil
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| | - Baolin Li
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| | - Kirk W Johnson
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| | - Jeffrey L Krajewski
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| | - Akihiko S Kato
- Department of Neuroscience, Lilly Research Laboratories, Indianapolis, IN, 46285.
| |
Collapse
|
2
|
Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, Swanson S, Catlow J, Witkin JM, Zwart R, Sher E, Choong KC, Wall TM, Schober D, Felder CC, Kato AS, Bredt DS, Nisenbaum ES. Modulation of TARP γ8–Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. J Pharmacol Exp Ther 2019; 369:345-363. [DOI: 10.1124/jpet.118.250126] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 03/06/2019] [Indexed: 12/30/2022] Open
|
3
|
Witkin JM, Schober DA, Gleason SD, Catlow JT, Porter WJ, Reel J, Jin X, Hobbs J, Gehlert D, Gernert DL, Gardinier KM, Kato AS, Ping X, Smith JL. Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611). CNSNDDT 2018; 16:1099-1110. [DOI: 10.2174/1871527316666171101132047] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 10/16/2017] [Accepted: 10/20/2017] [Indexed: 11/22/2022]
Affiliation(s)
- Jeffrey M. Witkin
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Douglas A. Schober
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Scott D. Gleason
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - John T. Catlow
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Warren J. Porter
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Jon Reel
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Xiaoming Jin
- Indiana University/Purdue University, Riley Hospital, Indianapolis, Indiana, United States
| | - Jonathan Hobbs
- Indiana University/Purdue University, Riley Hospital, Indianapolis, Indiana, United States
| | - Donald Gehlert
- Cerecor, Baltimore, MD (DG) and Matrix Pharmaceutical Consulting, Boulder, CO, United States
| | - Douglas L. Gernert
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Kevin M. Gardinier
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Akihiko S. Kato
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Xingjie Ping
- Indiana University/Purdue University, Riley Hospital, Indianapolis, Indiana, United States
| | - Jodi L. Smith
- Indiana University/Purdue University, Riley Hospital, Indianapolis, Indiana, United States
| |
Collapse
|
4
|
Abstract
The need for improved medications for psychiatric and neurological disorders is clear. Difficulties in finding such drugs demands that all strategic means be utilized for their invention. The discovery of forebrain specific AMPA receptor antagonists, which selectively block the specific combinations of principal and auxiliary subunits present in forebrain regions but spare targets in the cerebellum, was recently disclosed. This discovery raised the possibility that other auxiliary protein systems could be utilized to help identify new medicines. Discussion of the TARP-dependent AMPA receptor antagonists has been presented elsewhere. Here we review the diversity of protein complexes of neurotransmitter receptors in the nervous system to highlight the broad range of protein/protein drug targets. We briefly outline the structural basis of protein complexes as drug targets for G-protein-coupled receptors, voltage-gated ion channels, and ligand-gated ion channels. This review highlights heterodimers, subunit-specific receptor constructions, multiple signaling pathways, and auxiliary proteins with an emphasis on the later. We conclude that the use of auxiliary proteins in chemical compound screening could enhance the detection of specific, targeted drug searches and lead to novel and improved medicines for psychiatric and neurological disorders.
Collapse
Affiliation(s)
- Akihiko S Kato
- Neuroscience Discovery, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
| | - Jeffrey M Witkin
- Neuroscience Discovery, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA
| |
Collapse
|
5
|
Lee MR, Gardinier KM, Gernert DL, Schober DA, Wright RA, Wang H, Qian Y, Witkin JM, Nisenbaum ES, Kato AS. Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist. ACS Chem Neurosci 2017; 8:2631-2647. [PMID: 28825787 DOI: 10.1021/acschemneuro.7b00186] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The forebrain specific AMPA receptor antagonist, LY3130481/CERC-611, which selectively antagonizes the AMPA receptors associated with TARP γ-8, an auxiliary subunit enriched in the forebrain, has potent antiepileptic activities without motor side effects. We designated the compounds with such activities as γ-8 TARP dependent AMPA receptor antagonists (γ-8 TDAAs). In this work, we further investigated the mechanisms of action using a radiolabeled γ-8 TDAA and ternary structural modeling with mutational validations to characterize the LY3130481 binding to γ-8. The radioligand binding to the cells heterologously expressing GluA1 and/or γ-8 revealed that γ-8 TDAAs binds to γ-8 alone without AMPA receptors. Homology modeling of γ-8, based on the crystal structures of a distant TARP homologue, murine claudin 19, in conjunction with knowledge of two γ-8 residues previously identified as critical for the LY3130481 TARP-dependent selectivity provided the basis for a binding mode prediction. This allowed further rational mutational studies for characterization of the structural determinants in TARP γ-8 for LY3130481 activities, both thermodynamically as well as kinetically.
Collapse
Affiliation(s)
- Matthew R. Lee
- Lilly
Biotechnology Center, Eli Lilly and Company, 10300 Campus Point Dr. #200, San Diego, California 92121, United States
| | - Kevin M. Gardinier
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Douglas L. Gernert
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Douglas A. Schober
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Rebecca A. Wright
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - He Wang
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Yuewei Qian
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Jeffrey M. Witkin
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Eric S. Nisenbaum
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| | - Akihiko S. Kato
- Neuroscience
Discovery, Lilly Research Laboratory, 355 E Merril St., Indianapolis, Indiana 46285, United States
| |
Collapse
|
6
|
Kato AS, Witkin JM. Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611. Biochem Pharmacol 2017; 147:191-200. [PMID: 28987594 DOI: 10.1016/j.bcp.2017.09.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 09/27/2017] [Indexed: 12/11/2022]
Abstract
Drugs originate from the discovery of compounds, natural or synthetic, that bind to proteins (receptors, enzymes, transporters, etc.), the interaction of which modulates biological cascades that have potential therapeutic benefit. Rational strategies for identifying novel drug therapies are typically based on knowledge of the structure of the target proteins and the design of new chemical entities that modulate these proteins in a beneficial manner. The present review discusses a novel approach to drug discovery based on the identification and characterization of auxiliary proteins, the transmembrane AMPA receptor regulatory proteins (TARPs) that are associated with AMPA receptors. Utilizing these auxiliary proteins in compound screening led to the discovery of the TARP-dependent-AMPA forebrain selective receptor antagonist (TDAA), LY3130481/CERC-611 that is currently in clinical development for epilepsy.
Collapse
Affiliation(s)
- Akihiko S Kato
- Neuroscience Discovery Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0510, United States.
| | - Jeffrey M Witkin
- Neuroscience Discovery Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0510, United States.
| |
Collapse
|
7
|
Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA. Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors. Neuropharmacology 2017; 126:257-270. [PMID: 28757050 DOI: 10.1016/j.neuropharm.2017.07.028] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Revised: 06/27/2017] [Accepted: 07/26/2017] [Indexed: 11/18/2022]
Abstract
6-[(1S)-1-[1-[5-(2-hydroxyethoxy)-2-pyridyl]pyrazol-3-yl]ethyl]-3H-1,3-benzothiazol-2-one (LY3130481 or CERC-611) is a selective antagonist of AMPA receptors containing transmembrane AMPA receptor regulatory protein (TARP) γ-8. This molecule has been characterized as a potent and efficacious anticonvulsant in an array of acute and chronic epilepsy models in rodents. The present set of experiments was designed to assess the effects of LY3130481 on the electroencephelogram (EEG), cognitive function, and neurochemical outflow. LY3130481 disrupted food-maintained responding in rats and spontaneous alternation in a Y-maze in mice. In rat fear conditioning, LY3130481 caused a deficit in trace (hippocampal-dependent), but not in delay fear conditioning. Although these effects on cognitive performances were observed, the known cognitive-impairing anticonvulsant, topiramate, did not always produce deficits under these assay conditions. LY3130481 produced modest increases in wake times in rats. In addition, LY3130481 was able to attenuate some impairing effects of standard antiepileptic drugs. The motor-impairing effects of the lacosamide were attenuated by LY3130481 as was the decrease in non-rapid-eye movement sleep induced by carbamazepine. Evaluation of the effect of LY3130481 on neurotransmitter and metabolite efflux in the rat medial prefrontal cortex, using in vivo microdialysis, revealed significant increases in the pro-cognitive and wake-promoting neurotransmitters, histamine and acetylcholine, as well as in serotonin, telemethylhistamine, 5-HIAA, HVA and MHPG. LY3130481 thus presents a novel behavioral profile that will have to be evaluated in patients to fully appreciate its implications for therapeutics. LY3130481 is currently under clinical development as CERC-611 as an antiepileptic.
Collapse
Affiliation(s)
- Jeffrey M Witkin
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
| | - Jennifer Li
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Gary Gilmour
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Stephen N Mitchell
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Guy Carter
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Scott D Gleason
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Wesley F Seidel
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Brian J Eastwood
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Andrew McCarthy
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
| | - Warren J Porter
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Jon Reel
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Kevin M Gardinier
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Akihiko S Kato
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Keith A Wafford
- Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK.
| |
Collapse
|
8
|
Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, Luffer-Atlas D, Desai PV, Swanson S, Burris KD, Ding C, Heinz BA, Need AB, Barth VN, Stephenson GA, Diseroad BA, Woods TA, Yu H, Bredt D, Witkin JM. Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8. J Med Chem 2016; 59:4753-68. [PMID: 27067148 DOI: 10.1021/acs.jmedchem.6b00125] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Transmembrane AMPA receptor regulatory proteins (TARPs) are a family of scaffolding proteins that regulate AMPA receptor trafficking and function. TARP γ-8 is one member of this family and is highly expressed within the hippocampus relative to the cerebellum. A selective TARP γ-8-dependent AMPA receptor antagonist (TDAA) is an innovative approach to modulate AMPA receptors in specific brain regions to potentially increase the therapeutic index relative to known non-TARP-dependent AMPA antagonists. We describe here, for the first time, the discovery of a noncompetitive AMPA receptor antagonist that is dependent on the presence of TARP γ-8. Three major iteration cycles were employed to improve upon potency, CYP1A2-dependent challenges, and in vivo clearance. An optimized molecule, compound (-)-25 (LY3130481), was fully protective against pentylenetetrazole-induced convulsions in rats without the motor impairment associated with non-TARP-dependent AMPA receptor antagonists. Compound (-)-25 could be utilized to provide proof of concept for antiepileptic efficacy with reduced motor side effects in patients.
Collapse
Affiliation(s)
- Kevin M Gardinier
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Douglas L Gernert
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Warren J Porter
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Jon K Reel
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Paul L Ornstein
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Patrick Spinazze
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - F Craig Stevens
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Patric Hahn
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Sean P Hollinshead
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Daniel Mayhugh
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Jeff Schkeryantz
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Albert Khilevich
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Oscar De Frutos
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Scott D Gleason
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Akihiko S Kato
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Debra Luffer-Atlas
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Prashant V Desai
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Steven Swanson
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Kevin D Burris
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Chunjin Ding
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Beverly A Heinz
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Anne B Need
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Vanessa N Barth
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Gregory A Stephenson
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Benjamin A Diseroad
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Tim A Woods
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Hong Yu
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - David Bredt
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| | - Jeffrey M Witkin
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285 United States
| |
Collapse
|
9
|
Abstract
Transmembrane AMPA receptor regulatory proteins (TARPs) are auxiliary subunits that modulate AMPA receptor trafficking, gating and pharmacology throughout the brain. Why cornichon-2 (CNIH-2), another AMPA receptor-associated protein, modulates AMPA receptor gating and pharmacology in hippocampal neurons but not cerebellar granule neurons remains unresolved. Here, we report that CNIH-2 differentially impacts Type-Ia (γ-2 or γ-3) vs. Type-Ib (γ-4 or γ-8) TARP-containing AMPA receptors. Specifically, with AMPA receptors comprising γ-2, the cerebellar-enriched TARP isoform, CNIH-2 decreases I(KA) /I(Glu) ratio and decreases cyclothiazide efficacy while having minimal impact on recovery from desensitization and deactivation kinetics. By contrast, with AMPA receptors comprising γ-8, the hippocampal-enriched TARP isoform, we find that CNIH-2 slows deactivation kinetics, increases cyclothiazide potency and occludes a novel AMPA receptor kinetic phenomenon, namely resensitization. Additionally, we find that CNIH-2 differentially modulates the glutamate off-kinetics of γ-8-containing, but not γ-2-containing, AMPA receptors in a manner dependent upon the duration of agonist application. Together, these data demonstrate that the modulation of AMPA receptors by CNIH-2 depends upon the TARP isoform composition within the receptor complex.
Collapse
Affiliation(s)
- Martin B Gill
- Neuroscience Discovery Research and Clinical Investigation, Eli Lilly and Company, Indianapolis, IN 46285, USA.
| | | | | | | |
Collapse
|
10
|
Schober DA, Gill MB, Yu H, Gernert DL, Jeffries MW, Ornstein PL, Kato AS, Felder CC, Bredt DS. Transmembrane AMPA receptor regulatory proteins and cornichon-2 allosterically regulate AMPA receptor antagonists and potentiators. J Biol Chem 2011; 286:13134-42. [PMID: 21343286 DOI: 10.1074/jbc.m110.212522] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
AMPA receptors mediate fast excitatory transmission in the brain. Neuronal AMPA receptors comprise GluA pore-forming principal subunits and can associate with multiple modulatory components, including transmembrane AMPA receptor regulatory proteins (TARPs) and CNIHs (cornichons). AMPA receptor potentiators and non-competitive antagonists represent potential targets for a variety of neuropsychiatric disorders. Previous studies showed that the AMPA receptor antagonist GYKI-53655 displaces binding of a potentiator from brain receptors but not from recombinant GluA subunits. Here, we asked whether AMPA receptor modulatory subunits might resolve this discrepancy. We find that the cerebellar TARP, stargazin (γ-2), enhances the binding affinity of the AMPA receptor potentiator [(3)H]-LY450295 and confers sensitivity to displacement by non-competitive antagonists. In cerebellar membranes from stargazer mice, [(3)H]-LY450295 binding is reduced and relatively resistant to displacement by non-competitive antagonists. Coexpression of AMPA receptors with CNIH-2, which is expressed in the hippocampus and at low levels in the cerebellar Purkinje neurons, confers partial sensitivity of [(3)H]-LY450295 potentiator binding to displacement by non-competitive antagonists. Autoradiography of [(3)H]-LY450295 binding to stargazer and γ-8-deficient mouse brain sections, demonstrates that TARPs regulate the pharmacology of allosteric AMPA potentiators and antagonists in the cerebellum and hippocampus, respectively. These studies demonstrate that accessory proteins define AMPA receptor pharmacology by functionally linking allosteric AMPA receptor potentiator and antagonist sites.
Collapse
Affiliation(s)
- Douglas A Schober
- Discovery Neuroscience Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kato AS, Gill MB, Ho MT, Yu H, Tu Y, Siuda ER, Wang H, Qian YW, Nisenbaum ES, Tomita S, Bredt DS. Hippocampal AMPA receptor gating controlled by both TARP and cornichon proteins. Neuron 2011; 68:1082-96. [PMID: 21172611 DOI: 10.1016/j.neuron.2010.11.026] [Citation(s) in RCA: 138] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2010] [Indexed: 11/17/2022]
Abstract
Transmembrane AMPA receptor regulatory proteins (TARPs) and cornichon proteins (CNIH-2/3) independently modulate AMPA receptor trafficking and gating. However, the potential for interactions of these subunits within an AMPA receptor complex is unknown. Here, we find that TARPs γ-4, γ-7, and γ-8, but not γ-2, γ-3, or γ-5, cause AMPA receptors to "resensitize" upon continued glutamate application. With γ-8, resensitization occurs with all GluA subunit combinations; however, γ-8-containing hippocampal neurons do not display resensitization. In recombinant systems, CNIH-2 abrogates γ-8-mediated resensitization and modifies AMPA receptor pharmacology and gating to match that of hippocampal neurons. In hippocampus, γ-8 and CNIH-2 associate in postsynaptic densities and CNIH-2 protein levels are markedly diminished in γ-8 knockout mice. Manipulating neuronal CNIH-2 levels modulates the electrophysiological properties of extrasynaptic and synaptic γ-8-containing AMPA receptors. Thus, γ-8 and CNIH-2 functionally interact with common hippocampal AMPA receptor complexes to modulate synergistically kinetics and pharmacology.
Collapse
Affiliation(s)
- Akihiko S Kato
- Department of Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kato AS, Gill MB, Yu H, Nisenbaum ES, Bredt DS. TARPs differentially decorate AMPA receptors to specify neuropharmacology. Trends Neurosci 2010; 33:241-8. [PMID: 20219255 DOI: 10.1016/j.tins.2010.02.004] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2009] [Revised: 02/11/2010] [Accepted: 02/13/2010] [Indexed: 11/30/2022]
Abstract
Transmembrane AMPA receptor regulatory proteins (TARPs) are the first identified auxiliary subunits for a neurotransmitter-gated ion channel. Although initial studies found that stargazin, the prototypical TARP, principally chaperones AMPA receptors, subsequent research demonstrated that it also regulates AMPA receptor kinetics and synaptic waveforms. Recent studies have identified a diverse collection of TARP isoforms--types Ia, Ib II--that distinctly regulate AMPA receptor trafficking, gating and neuropharmacology. These TARP isoforms are heterogeneously expressed in specific neuronal populations and can differentially sculpt synaptic transmission and plasticity. Whole-genome analyses also link multiple TARP loci to childhood epilepsy, schizophrenia and bipolar disorder. TARPs emerge as vital components of excitatory synapses that participate both in signal transduction and in neuropsychiatric disorders.
Collapse
Affiliation(s)
- Akihiko S Kato
- Department of Neuroscience, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285-0510, USA
| | | | | | | | | |
Collapse
|
13
|
|
14
|
Kato AS, Siuda ER, Nisenbaum ES, Bredt DS. AMPA Receptor Subunit-Specific Regulation by a Distinct Family of Type II TARPs. Neuron 2008; 59:986-96. [DOI: 10.1016/j.neuron.2008.07.034] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2008] [Revised: 05/20/2008] [Accepted: 07/25/2008] [Indexed: 10/21/2022]
|
15
|
Kato AS, Bredt DS. Pharmacological regulation of ion channels by auxiliary subunits. Curr Opin Drug Discov Devel 2007; 10:565-72. [PMID: 17786855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Ion channels link environmental stimuli to intracellular signaling pathways. Channel proteins often occur in macromolecular complexes in association with auxiliary subunits that control channel trafficking, gating and pharmacology. A large number of drugs exert their therapeutic effects by regulating ion channel activity and downstream signaling. These drugs can target either the principle ion channel or the associated auxiliary subunits. Sulfonylurea-type antidiabetics and gabapentin-type anticonvulsants exemplify important therapeutics that bind to ion channel auxiliary subunits. The recent molecular characterization of neuronal glutamate receptor ion channel complexes identified auxiliary subunits and associated proteins that may provide new targets for treating psychiatric and neurodegenerative diseases.
Collapse
Affiliation(s)
- Akihiko S Kato
- Neuroscience Discovery, Lilly Research Laboratories, Eli Lilly & Co, Indianapolis, IN 46285, USA.
| | | |
Collapse
|
16
|
Kato AS, Zhou W, Milstein AD, Knierman MD, Siuda ER, Dotzlaf JE, Yu H, Hale JE, Nisenbaum ES, Nicoll RA, Bredt DS. New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors. J Neurosci 2007; 27:4969-77. [PMID: 17475805 PMCID: PMC6672084 DOI: 10.1523/jneurosci.5561-06.2007] [Citation(s) in RCA: 113] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AMPA-type glutamate receptors (GluRs) mediate most excitatory signaling in the brain and are composed of GluR principal subunits and transmembrane AMPA receptor regulatory protein (TARP) auxiliary subunits. Previous studies identified four mammalian TARPs, gamma-2 (or stargazin), gamma-3, gamma-4, and gamma-8, that control AMPA receptor trafficking, gating, and pharmacology. Here, we explore roles for the homologous gamma-5 and gamma-7 proteins, which were previously suggested not to serve as TARPs. Western blotting reveals high levels of gamma-5 and gamma-7 in the cerebellum, where gamma-7 is enriched in Purkinje neurons in the molecular layer and glomerular synapses in the granule cell layer. Immunoprecipitation proteomics shows that cerebellar gamma-7 avidly and selectively binds to AMPA receptor GluR subunits and also binds to the AMPA receptor clustering protein, postsynaptic density-95 (PSD-95). Furthermore, gamma-7 occurs together with PSD-95 and AMPA receptor subunits in purified postsynaptic densities. In heterologous cells, gamma-7 but not gamma-5 greatly enhances AMPA receptor glutamate-evoked currents and modulates channel gating. In granule cells from stargazer mice, transfection of gamma-7 but not gamma-5 increases AMPA receptor-mediated currents. Compared with stargazin, gamma-7 differentially modulates AMPA receptor glutamate affinity and kainate efficacy. These studies define gamma-7 as a new member of the TARP family that can differentially influence AMPA receptors in cerebellar neurons.
Collapse
Affiliation(s)
| | - Wei Zhou
- Departments of Physiology, and Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94143
| | - Aaron D. Milstein
- Departments of Physiology, and Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94143
| | | | | | | | | | | | | | - Roger A. Nicoll
- Departments of Physiology, and Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94143
| | - David S. Bredt
- Neuroscience Discovery and
- Integrated Biology, Lilly Research Laboratories
| |
Collapse
|
17
|
Imura N, Kato AS, Novo NF, Hata G, Uemura M, Toda T. A comparison of mesial molar root canal preparations using two engine-driven instruments and the balanced-force technique. J Endod 2001; 27:627-31. [PMID: 11592493 DOI: 10.1097/00004770-200110000-00008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The purpose of this study was to compare the effects of two engine-driven, nickel-titanium instrument systems with hand files in the final shape of slight and moderately curved canals. A total of 72 mesial roots of extracted human mandibular molars were divided into three groups: ProFile .04 taper, Pow-R rotary systems, and Flex-R hand-filing technique. The roots were mounted and cross-sectioned at two different horizontal levels using a modified Bramante technique. Pre- and postinstrumented cross-sectional roots were imaged, recorded, and computer analyzed. Results showed that, at the middle third, in almost all groups, there was a tendency of cutting more toward the mesial side with only one exception: Pow-R cut more to the distal side (danger zone) (p < 0.02). At the apical third, Flex-R (p < 0.03) and ProFile (0.001) transported to the mesial side (danger zone) when the curvature increased. When the three techniques were compared analyzing each side and considering the two groups of curvature, at the middle third in the moderately curved-canal group, Flex-R cut statistically more than Pow-R toward the lingual side. The other comparisons showed no statistically significant difference. When the techniques were compared in relation with the degree of curvature, in the apical third, ProFile .04 cut statistically more toward the mesial side in the moderately curved canal group than in the slightly curved canal group. The other comparisons showed no statistically significant difference. Canal preparation time was shorter with hand instrumentation (p < .05) in a few instances.
Collapse
Affiliation(s)
- N Imura
- Ensino Odontológico Institute, PAEO, Sào Paulo, Brazil
| | | | | | | | | | | |
Collapse
|
18
|
Imura N, Kato AS, Hata GI, Uemura M, Toda T, Weine F. A comparison of the relative efficacies of four hand and rotary instrumentation techniques during endodontic retreatment. Int Endod J 2000; 33:361-6. [PMID: 11307212 DOI: 10.1046/j.1365-2591.2000.00320.x] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIM The purpose of this study was to quantify the amount of remaining gutta-percha/scaler on the walls of root canals when two engine-driven instruments (Quantec and ProFile) and two hand instruments (K-file and Hedström file) were used to remove these materials. The amount of apically extruded debris and the time required for treatment were also recorded. METHODOLOGY One hundred extracted mandibular premolars were prepared using a modified step-back, flare technique and obturated with the lateral condensation technique. After repreparation with the test instruments, the specimens were cut transversally at the cervical, middle and apical thirds with steel discs and the three sections were split longitudinally. The amount of residual debris on the canal walls in each section was examined using a stereomicroscope. RESULTS In all groups the cervical and middle thirds showed no debris. In the apical third, obturating material was observed in some specimens. No statistically significant difference was found between the two groups for incidence of debris, although the Hedström group showed a greater number of samples with remaining gutta-percha/sealer. When analysing dirty specimens only, there was a statistically significant difference between the four groups (P < 0.01) with the Hedström group having significantly less length of canal wall with remaining obturation material than the Quantec group. There was no significant difference amongst the groups for weight of extruded debris. However, there was a significant difference amongst the groups for mean treatment time with the Hedström file group requiring significantly less time than the Quantec group (P < 0.001); no significant differences were found between the other groups. Six instruments fractured in the Quantec group, four in the ProFile group, two in the Hedström group and two in the K-type group. CONCLUSIONS The results showed that overall, all instruments may leave filling material inside the root canal. During retreatment there is a risk of instrument breakage, especially rotary instruments.
Collapse
Affiliation(s)
- N Imura
- Department of Endodontics, Osaka Dental University, Osaka, Japan
| | | | | | | | | | | |
Collapse
|